- Home
- ICON vs XBIO Comparison
ICON vs XBIO Comparison
Compare ICON & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- XBIO
- Stock Information
- Founded
- ICON 2023
- XBIO N/A
- Country
- ICON Greece
- XBIO United States
- Employees
- ICON N/A
- XBIO N/A
- Industry
- ICON
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- XBIO Health Care
- Exchange
- ICON Nasdaq
- XBIO Nasdaq
- Market Cap
- ICON 3.6M
- XBIO 4.2M
- IPO Year
- ICON 2024
- XBIO N/A
- Fundamental
- Price
- ICON $1.79
- XBIO $2.91
- Analyst Decision
- ICON Strong Buy
- XBIO Hold
- Analyst Count
- ICON 1
- XBIO 1
- Target Price
- ICON $4.50
- XBIO N/A
- AVG Volume (30 Days)
- ICON 116.0K
- XBIO 9.5K
- Earning Date
- ICON 05-23-2025
- XBIO 05-13-2025
- Dividend Yield
- ICON 195.06%
- XBIO N/A
- EPS Growth
- ICON N/A
- XBIO N/A
- EPS
- ICON N/A
- XBIO N/A
- Revenue
- ICON $5,309,000.00
- XBIO $2,582,728.00
- Revenue This Year
- ICON $76.76
- XBIO $14.23
- Revenue Next Year
- ICON $30.43
- XBIO N/A
- P/E Ratio
- ICON N/A
- XBIO N/A
- Revenue Growth
- ICON 18.61
- XBIO 5.63
- 52 Week Low
- ICON $1.60
- XBIO $2.20
- 52 Week High
- ICON $154.00
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- XBIO 49.56
- Support Level
- ICON N/A
- XBIO $2.78
- Resistance Level
- ICON N/A
- XBIO $3.22
- Average True Range (ATR)
- ICON 0.00
- XBIO 0.24
- MACD
- ICON 0.00
- XBIO 0.03
- Stochastic Oscillator
- ICON 0.00
- XBIO 34.16
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.